Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee
Summary of Main Points from the Meeting held on the 10th March 2014

2. Minutes and Summary Notes from last meeting
The Minutes and Summary notes from the February 2014 meeting were approved and will be circulated.

3. Matters Arising
The Committee noted the matters arising from the previous meeting.

4. New Medicines Applications
Full applications

- **Prilocaine (Prilotekal®)**

Decision: Approved
For spinal anaesthesia in short term surgical procedures in Obstetrics. Prilotekal® will be used in place of Heavy Bupivacaine 0.5% over which it confers additional benefits as it has a more rapid offset of action leading to more rapid discharge of patients following simple cervical procedures.

- **Hydrocortisone MR (Plenadren®)**

Decision: Not approved
Licensed for replacement in adrenal insufficiency. Plenadren® was not approved for addition to the formulary on the basis of there being a lack of evidence that demonstrates clinical benefit of this formulation over the standard release formulations. In addition, there is a lack of evidence that demonstrates that the once daily administration regimen confers a positive outcome over conventional dosing regimens. As a result the panel did not consider the MR formulation to be a cost-effective option.

- **Fingolimod (Gilenya®)**

Decision: Approved
In line with NICE Guidance TA 254 for highly active relapsing remitting Multiple Sclerosis.

Ex-Panel requests

- **National Cancer Drugs Fund and list**

The following 16 drugs were approved for inclusion in the formulary which have been previously approved for use by the NHS England National Cancer Drugs Fund:

- Axitinib
- Bosutinib
- Brentuximab
- Cabazitaxel
- Cetuximab
- Clorafabine
- Crizotinib
- Enzalutamide
- Everolimus
- Nelarabine
- Ofatumumab
- Pomalidomide
- Ponatinib
- Ruxolitinib
- Temsirolimus
- Vismodegib

Application forms for noting
The following application forms were noted:

- Octriplasmin - In line with NICE TA297 (Added to formulary in December 2013)
- Fluocinolone intravitrael implant - In line with NICE TA301 (Added to formulary in December 2013)
- Teriflunomide - In line with NICE TA303 (Added to formulary in February 2014)

Feedback from the NWLIF panel meeting
Feedback was provided from the NWLIF panel meeting which was held in January 2014.

5. Medicines Management/Trust Medicines Policy

- **Trust Medicines Policy: Section 8 - Administration of medicines**

Decision: Approved
Scheduled review with minor amendments.

- **Trust Medicines Policy: Section 2 - Prescribing**

Decision: Approved
Scheduled review with minor amendments.

- **Trust Medicines Policy: Appendix 2. Critical list of omitted and delayed medicines**

Decision: Approved
Scheduled review with minor amendments.

7. NICE TA Guidance

- **TA304 - Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip**

Prostheses for total hip replacement and resurfacing arthroplasty are recommended as treatment options for people with end-stage arthritis of the hip only if the prostheses have rates (or projected rates) of revision of 5% or less at 10 years.

Action: Nil (Does not affect the formulary)

- **TA305 - Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion**
  Aflibercept solution for injection is recommended as an option for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion only if the manufacturer provides aflibercept solution for injection with the discount agreed in the patient access scheme

Action: Nil (Currently on the formulary)

- **TA306 - Pixantrone monotherapy for treating multiply relapsed or refractory aggressive Non-Hodgkin's B-cell lymphoma**
  Pixantrone monotherapy is recommended as an option for treating adults with multiply relapsed or refractory aggressive non-Hodgkin's B-cell lymphoma only if:
  - the person has previously been treated with rituximab **and**
  - the person is receiving third- or fourth-line treatment **and**
  - the manufacturer provides pixantrone with the discount agreed in the patient access scheme.

Action: Added to the formulary in line with NICE Guidance

8. IVIG Update

The panel noted the IVIG report.
There were 10 IVIG issues in February 2014, with 7 new requests:

- Two for Idiotypic Thrombocytopaenic Purpura (Red indication)
- One for Guillain Barre Syndrome (Red indication)
- One for Chronic Inflammatory Demyelinating Polyradiculoneuropathy (Red indication)
- One for Kawasaki's Disease (Red indication)
- One for Myasthenia Gravis (Blue indication)
- One for Acquired Cell Plasia (Blue indication)

9. Items for Noting

- **Safe storage of medicines audit report - Nov 2013**

On-Site locations: 45 sites out of 59 were included in the audit. Of the 19 standards 15 demonstrated compliance >80% and 3 standard > 70%.

Off-Site locations: 8 sites out of 16 were included in the audit. Of the 19 standards 17 demonstrated compliance >80% and 1 standard > 70%.

Action: Action plan to be drafted in collaboration with SNMC in response to the audit findings.

- **Home Office and Wholesaler Dealers License**

Guidance on how to make an application for Home Office and Wholesaler Dealer's licenses. Pharmacy will be making an application for both licenses. Pharmacy will also undertake a risk assessment to assess the impact of not having these licenses in place whilst awaiting for them to be granted.

- **Quarterly CD Summary Report - Q3 2013/14**

Noted

- **Controlled Drug Occurrence Report - Q3 2013/14**

Noted

- **Category A and B Unlicensed Medicinal Products**

Noted

- **MHRA Drug Safety Update Feb 2014**

Noted
The following papers should be sent to the Trust Quality Committee:

- Medicines Committee Summary Notes - December 2013
- Medicines Committee Terms of Reference - February 2014

11. Date of the next meeting

Monday 7th April 2014, 8.00 - 9.00 – Pathology Seminar Room, 1st Floor
Closing date for papers: Friday 14th March 2014

Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee